Publications by authors named "E Gennaro"
Head and neck cancers (HNCs) are the sixth most commonly diagnosed cancer and the eighth leading cause of cancer-related mortality worldwide, with squamous cell carcinoma being the most prevalent type. The global incidence of HNCs is steadily increasing, projected to rise by approximately 30% per year by 2030, a trend observed in both developed and undeveloped countries. This study involved serum proteomic profiling to identify predictive clinical biomarkers in cancer patients undergoing chemoradiotherapy (CRT).
View Article and Find Full Text PDFThe management of neuroendocrine neoplasms (NENs) involves the measurement of serum chromogranin A (s-CGA), serum neuro-specific enolase (s-NSE), and urinary 5-hydroxindolacetic acid (5-HIAA). Urinary para-hydroxyphenylacetic acid (u-pHPAA), a metabolite of tyrosine, has been proposed as a potential biomarker for these diseases. This study aims to evaluate the effectiveness of u-pHPAA and tyrosine as biomarkers.
View Article and Find Full Text PDFBackground: Despite advancements in therapeutic approaches, including taxane-based chemotherapy and androgen receptor-targeting agents, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable tumor, highlighting the need for novel strategies that can target the complexities of this disease and bypass the development of drug resistance mechanisms. We previously demonstrated the synergistic antitumor interaction of valproic acid (VPA), an antiepileptic agent with histone deacetylase inhibitory activity, with the lipid-lowering drug simvastatin (SIM). This combination sensitizes mCRPC cells to docetaxel treatment both in vitro and in vivo by targeting the cancer stem cell compartment via mevalonate pathway/YAP axis modulation.
View Article and Find Full Text PDFRandomized phase 2 study of valproic acid combined with simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic pancreatic adenocarcinoma patients: the VESPA trial study protocol.
BMC Cancer
September 2024
Article Synopsis
- Metastatic pancreatic ductal adenocarcinoma (mPDAC) has a poor prognosis, leading researchers to explore the repurposing of existing drugs like valproic acid (VPA) and statins for potentially more effective treatments alongside standard chemotherapy.* -
- The VESPA clinical trial is designed to investigate the combination of VPA and simvastatin (SIM) with gemcitabine/nab-paclitaxel in mPDAC patients, aiming to enhance treatment efficacy compared to chemotherapy alone.* -
- The trial will enroll 240 patients across multiple centers, assessing outcomes like progression-free survival and overall survival, with a hypothesis that the combination therapy could extend progression-free survival from 6 to
Article Synopsis
- Pancreatic cancer is hard to treat because it's often diagnosed at an advanced stage, lacks early symptoms, and has few reliable biomarkers for detection.
- *Recent research shows that interactions between cancer and immune cells in both the tumor micro-environment and distant areas of the body (macro-environment) play a crucial role in tumor growth and immune response.
- *Understanding how these environments interact may lead to new early detection methods and therapies for pancreatic cancer through identifying molecular targets and improving diagnostic biomarkers.